Cynata in 10, page-42

@singhgu have attached a research report from Pitt St research from last November. Though a paid report it is a good background piece in case you haven't already seen it.
Since this report we have OA trial underway. Expansion of Covid trial to now be recruiting any ARDS patients in ICU. Deal due with Tekcyte to progress the Diabetic Foot Ulcer treatment and therefore Phase 2 trial in this indication.
Other trials to still be announced and in the pipeline GvHD with Fujifilm. Renal trial as well as Critical Limb Ischemia which Cynatas original pre clinical testing was focussed on. All now straight to Phase 2.
At the time of writing this report the stock was at 80c. Now with much progress.
Hope it is of help
Just had another read of it myself. Pretty compelling
IMV with a big soak at these levels (and probably losing a lot of smaller retail investors on the way down from the last run) the next news should see this move up quickly as I can't imagine there will be a lot of loose stock.
All just my opinion so please don't take this as advice.
Good luck with it.
GLTAH